JP2007528216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007528216A5 JP2007528216A5 JP2006550491A JP2006550491A JP2007528216A5 JP 2007528216 A5 JP2007528216 A5 JP 2007528216A5 JP 2006550491 A JP2006550491 A JP 2006550491A JP 2006550491 A JP2006550491 A JP 2006550491A JP 2007528216 A5 JP2007528216 A5 JP 2007528216A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- fibrosis
- modified
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 108091028664 Ribonucleotide Proteins 0.000 claims 6
- 239000002336 ribonucleotide Substances 0.000 claims 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 108091081021 Sense strand Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54068704P | 2004-01-30 | 2004-01-30 | |
| US60/540,687 | 2004-01-30 | ||
| US64152205P | 2005-01-04 | 2005-01-04 | |
| US60/641,522 | 2005-01-04 | ||
| PCT/IL2005/000102 WO2005072057A2 (en) | 2004-01-30 | 2005-01-27 | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011083817A Division JP2011172579A (ja) | 2004-01-30 | 2011-04-05 | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007528216A JP2007528216A (ja) | 2007-10-11 |
| JP2007528216A5 true JP2007528216A5 (https=) | 2008-03-13 |
| JP4755113B2 JP4755113B2 (ja) | 2011-08-24 |
Family
ID=34830511
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550491A Expired - Fee Related JP4755113B2 (ja) | 2004-01-30 | 2005-01-27 | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
| JP2011083817A Pending JP2011172579A (ja) | 2004-01-30 | 2011-04-05 | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011083817A Pending JP2011172579A (ja) | 2004-01-30 | 2011-04-05 | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20050197310A1 (https=) |
| EP (2) | EP2330111A3 (https=) |
| JP (2) | JP4755113B2 (https=) |
| AT (1) | ATE491715T1 (https=) |
| DE (1) | DE602005025347D1 (https=) |
| WO (1) | WO2005072057A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4755113B2 (ja) * | 2004-01-30 | 2011-08-24 | クアーク・ファーマスーティカルス、インコーポレイテッド | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
| US20100266574A1 (en) * | 2005-06-10 | 2010-10-21 | Orna Mor | Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases |
| WO2008063760A2 (en) * | 2006-10-18 | 2008-05-29 | The University Of Texas M.D. Anderson Cancer Center | Methods for treating cancer targeting transglutaminase |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| WO2008152636A2 (en) * | 2007-06-15 | 2008-12-18 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting nadph oxidase expression |
| US9051568B2 (en) | 2008-04-25 | 2015-06-09 | Rutgers, The State University Of New Jersey | Anti-sense microrna expression vectors |
| US20140050779A1 (en) * | 2011-02-09 | 2014-02-20 | Singapore Health Services Pte. Ltd. | Transglutaminase-2 inhibitors and uses thereof |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| US9234048B2 (en) | 2012-01-18 | 2016-01-12 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
| US9732101B2 (en) | 2012-01-18 | 2017-08-15 | Wisconsin Alumni Research Foundation | Bioreversible boronates for delivery of molecules into cells |
| US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
| EP2895200B1 (en) | 2012-09-14 | 2019-11-06 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
| KR101881662B1 (ko) * | 2016-05-12 | 2018-07-26 | 강원대학교산학협력단 | 당뇨성 합병증 예방 및 치료용 약제학적 조성물 및 당뇨성 합병증 예방 또는 치료제 스크리닝 방법 |
| US10155948B2 (en) | 2016-05-12 | 2018-12-18 | Kangwon National University University-Industry Cooperation Foundation and | Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| IT201800009133A1 (it) * | 2018-10-03 | 2020-04-03 | Università Cattolica del Sacro Cuore | Identificazione di biomarcatori molecolari predittivi di risposta al trattamento radiochemoterapico nel carcinoma della cervice |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| EP4507702A2 (en) * | 2022-04-14 | 2025-02-19 | ARO Biotherapeutics Company | Fn3 domain-sirna conjugates with enzyme replacement therapy |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5021440A (en) | 1989-07-31 | 1991-06-04 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
| US5098707A (en) | 1989-07-31 | 1992-03-24 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
| US4968713A (en) | 1989-07-31 | 1990-11-06 | Merck & Co., Inc. | Certain imidazole compounds as transglutaminase inhibitors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| WO1998004245A1 (en) * | 1996-07-25 | 1998-02-05 | The Victoria University Of Manchester | Use of transglutaminase modulators to promote wound healing |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| AU771579B2 (en) | 1998-10-26 | 2004-03-25 | Avi Biopharma, Inc. | p53 antisense agent and method |
| US6773916B1 (en) * | 1999-01-05 | 2004-08-10 | The Flinders University Of South Australia | Agents and methods for treatment and diagnosis of ocular disorders |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| PT1309726E (pt) * | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| AU2002305236A1 (en) * | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
| US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| JP2005517423A (ja) * | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸（ｓｉＮＡ）を用いるＴＧＦ−ベータおよびＴＧＦ−ベータレセプター遺伝子の発現のＲＮＡ干渉媒介性阻害 |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| AU2003260370B2 (en) * | 2002-08-05 | 2008-05-22 | Silence Therapeutics Gmbh | Further novel forms of interfering RNA molecules |
| AU2003286746A1 (en) * | 2002-10-29 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| EP1644475A4 (en) * | 2003-06-20 | 2009-06-03 | Isis Pharmaceuticals Inc | DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION |
| JP4755113B2 (ja) * | 2004-01-30 | 2011-08-24 | クアーク・ファーマスーティカルス、インコーポレイテッド | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
-
2005
- 2005-01-27 JP JP2006550491A patent/JP4755113B2/ja not_active Expired - Fee Related
- 2005-01-27 DE DE602005025347T patent/DE602005025347D1/de not_active Expired - Lifetime
- 2005-01-27 US US11/045,780 patent/US20050197310A1/en not_active Abandoned
- 2005-01-27 EP EP10179637A patent/EP2330111A3/en not_active Withdrawn
- 2005-01-27 EP EP05703145A patent/EP1758998B1/en not_active Expired - Lifetime
- 2005-01-27 WO PCT/IL2005/000102 patent/WO2005072057A2/en not_active Ceased
- 2005-01-27 AT AT05703145T patent/ATE491715T1/de not_active IP Right Cessation
-
2008
- 2008-02-28 US US12/072,941 patent/US7939652B2/en active Active
-
2011
- 2011-04-05 JP JP2011083817A patent/JP2011172579A/ja active Pending
- 2011-04-22 US US13/092,501 patent/US8198258B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007528216A5 (https=) | ||
| JP7791222B2 (ja) | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド | |
| US11505569B2 (en) | GalNAc phosphoramidites, nucleic acid conjugates thereof and their use | |
| CN101932709B (zh) | 靶向雄激素受体的lna拮抗剂 | |
| JP2009536664A5 (https=) | ||
| RU2653438C2 (ru) | Конъюгаты олигонуклеотидов | |
| JP2009536037A5 (https=) | ||
| JP2009536222A5 (https=) | ||
| JP2011172579A5 (https=) | ||
| JP2008510019A5 (https=) | ||
| CA2524255A1 (en) | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure | |
| JP2007515175A (ja) | Ｂｃｌ−２のモデュレーションのためのオリゴマー化合物 | |
| JP2009517048A5 (https=) | ||
| CN104955952A (zh) | Lna寡核苷酸碳水化合物缀合物 | |
| JP2013514761A5 (https=) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2010524486A (ja) | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 | |
| BR112020007417A2 (pt) | molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b | |
| WO2011084694A1 (en) | Stabilized stat3 decoy oligonucleotides and uses therefor | |
| JP2006502243A5 (https=) | ||
| JP2011527901A (ja) | Ｇｌｉ２を標的化するｒｎａアンタゴニスト | |
| JP2011505798A (ja) | Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物 | |
| JP2010539961A (ja) | ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物 | |
| WO2012007477A1 (en) | Anti hcv oligomers | |
| RU2007116168A (ru) | Олигорибонуклеотиды и способы их применения для лечения алопеции, острой почечной недостаточности и других заболеваний |